AMR Bio - company
1 known investors
Find your way into AMR Bio - company
AMR Bio develops XF-73, a first-in-class topical antimicrobial candidate in Phase 3 trials designed to prevent post-surgical infections, with the lead program targeting pre-operative decolonization in surgical settings. The company also advances dermal formulations for severe wound and skin infections.
Investors · 1
Frequently asked questions
- What does AMR Bio - company do?
- AMR Bio develops XF-73, a first-in-class topical antimicrobial candidate in Phase 3 trials designed to prevent post-surgical infections, with the lead program targeting pre-operative decolonization in surgical settings. The company also advances dermal formulations for severe wound and skin infections.
- Who are AMR Bio - company's investors?
- AMR Bio - company's investors include EMV Capital.